Key facts
- Notable investors include U.S. Department of Health and Human Services, Zhongzhi Pharmaceutical Holdings.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for GABAeron
- ·The full record, as it builds
Funding rounds
No funding rounds for GABAeron are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About GABAeron
Operator of a biopharmaceutical company intended to develop therapies using stem cells and small molecules to treat neurological diseases. The company takes a novel approach that combines precision medicine using genetic information for patient stratification with regenerative medicine using human iPSC-derived cell products for therapy and pharmacological intervention, providing healthcare professionals with therapeutic programs to replace or protect vulnerable brain cell populations to restore and preserve brain functions.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2017
- Employees
- 10
- Website
- gabaeron.com/
- Ownership
- Privately Held (backing)
GABAeron doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in GABAeron shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on GABAeron in its N-PORT filings yet. We sweep new filings monthly.